A major concern for Missourians, and possibly more across the US, is how medical marijuana will affect their eligibility for welfare. People who apply can be screened for drug use, and this may hinder people from receiving their necessary treatment http://bit.ly/317Hn20
Still in the early stages, biosynthesis of cannabinoids using fermentative microbes could diminish dependency on plants to extract cannabinoids and help control dosage for medical patients. This is still in the works but could be very cost efficient long term for all involved http://bit.ly/315Lcof
“More baby boomers use medical marijuana, but they want their doctors to get wise to the risks and benefits” – Exactly what CED Foundation brings to the industry.
Study finds that baby boomers want more education, more research, and greater openness with their health-care providers about using medical marijuana. https://on.mktw.net/2WbBqNG
After a public hearing on Friday where researchers and health professionals urged the FDA to increase research into cannabis, FDA official Dr. Amy Abernethy tweeted, “We will work as quickly as possible to define a way forward.” The FDA is accepting further comments on a docket until July 2; it then plans to convene a workgroup co-chaired by Abernethy and Lowell Schiller to examine its next steps. http://bit.ly/2WevL9M
After vetoing legislation that would have expanded Iowa’s medical marijuana program, governor Kim Reynolds now says that she’d support ‘narrow and cautious’ expansion of medical cannabis law. Though patients using cannabis oils, creams, and pills need higher doses of cannabis to manage their pain, Reynolds told reporters, “I just felt [the bill] was too much of a jump.” http://bit.ly/2KnJwAF
Christine Stenquist is one of many American patients who uses cannabis to manage her addiction to opioids. She has now taken to Utah’s Capitol Hill to educate lawmakers on the benefits of medicinal marijuana. http://bit.ly/2KrroWv
A fascinating session titled “Is There a role for Cannabis in Cancer Symptom Management?” was held yesterday at the 2019 American Cancer Society Annual Meeting.
Bottom line: only once cannabis is legal on a federal level will there be sufficient research about the risks and benefits of cannabis use in patients with cancer. http://bit.ly/2Kq2ruD
On Sunday, the Illinois Senate approved legislation that makes Illinois’ 2013 medical marijuana program permanent. The bill also expands the qualifying conditions for patients to be eligible for a prescription for medicinal cannabis, including migraines, irritable bowel syndrome, Crohn’s disease and anorexia nervosa. http://bit.ly/2Kplo0q
Silymarin is a natural compound called a flavonoid, which happens to have antioxidant and liver protecting activities. Over many years, it has been proposed as a complementary medicine to reduce the liver injury produced by other medications. Interestingly, it happens to have anti-inflammatory properties and the ability to kill some bacteria. This flavonoid, Silymarin, is found in Milk Thistle… as well as Cannabis..and it seems to have “a significant therapeutic effect []administered alone, or in combination with chemotherapy, in [helping to treat] tuberculosis caused by drug-sensitive or drug-resistant strains[, findings represented here in both] in vitro and in vivo studies”
For many years, Tuberculosis (TB) has been a devastating public health problem, internationally. The treatment of this bacteria has been very limited and loaded with challenges. There is a constant cat/mouse chase between nature and human medicine, as the bacteria continually evolves to out-compete new drugs that are developed to treat it.
Here, yet another amazing potential breakthrough that cannabis brings to the table. Among the other flavonoids besides Silymarin: Orientin, Quercetin, and Kaempferol.
Of note: Silymarin happens to inhibit some liver enzymes, CYP-3A4 and CYP-2C9, which happen to be some of the liver enzymes which help break down cannabis metabolites.
This paper is stored here: http://bit.ly/2IgOLiG inside the CED Foundation Archive
To explore related literature, click keywords below the images:
Cannabidiol in the Treatment of Post-Traumatic Stress Disorder: A Case Series
Preliminary findings from a study conducted on PTSD patients open a new door for cannabidiol (CBD) as a potential supplementary treatment option. CBD indirectly activates receptors linked to behavioral responses to aversive memories, a major component of the suffering involved in PTSD. The majority of participants in this review reported a decrease in the prevalence and severity of PTSD symptoms, both in the short-, and long-term. It should be taken into consideration that this study was performed with a small sample size that lacked a placebo or control group; however, this tells a familiar story to what we see in clinic. Further research will likely support cannabinoids as a legitimate treatment option for PTSD. Under the guidance of a knowledgeable Cannabis Medicine provider, PTSD patients may also consider supplementing their current treatment plan with CBD
Read more or download PDF on the CED Foundation Archive: http://bit.ly/2Kf9INN
